ASCO guidelines

This page is a gathering place for the American Society of Clinical Oncology (ASCO) guidelines that do not clearly fit under a disease-specific page. This link will take you to the landing page for all ASCO Guidelines, Tools, & Resources. For more general guidelines, please visit this page.
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
=Guidelines=
==Bone-modifying agents==
*2022: Eisen et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update EuroPMC
**2017: Dhesy-Thind et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline EuroPMC
**2003: Hillner et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer EuroPMC
**2000: Hillner et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer: American Society of Clinical Oncology Bisphosphonates Expert Panel EuroPMC
*2017: Van Poznak et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update EuroPMC
*2002: Berenson et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma EuroPMC
==Cancer cachexia==
*2023: Roeland et al. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update EuroPMC
**2020: Roeland et al. Management of Cancer Cachexia: ASCO Guideline EuroPMC
==Cannabis and Cannabinoids==
*2024: Braun et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline EuroPMC
==Chemotherapy-induced peripheral neuropathy==
*2020: Loprinzi et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update EuroPMC
**2014: Hershman et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline EuroPMC
==Dyspnea==
*2021: Hui et al. Management of Dyspnea in Advanced Cancer: ASCO Guideline EuroPMC
==Genetic and genomic testing==
*2024: Tung et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline EuroPMC
*2022: Chakravarty et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion EuroPMC
*2016: Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 EuroPMC
**2009: Allegra et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy EuroPMC
*2011: Keedy et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy EuroPMC
==Infectious diseases==
*2024: Kamboj et al. Vaccination of Adults With Cancer: ASCO Guideline link to PMC article EuroPMC
*2020: Hwang et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update EuroPMC
**2015: Hwang et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update EuroPMC
**2010: Artz et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases EuroPMC
*2018: Taplitz et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update EuroPMC
**2013: Flowers et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline EuroPMC
==Obesity==
*2021: Griggs et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update EuroPMC
**2012: Griggs et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline EuroPMC
==Pain==
*2023: Paice et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline EuroPMC
==Screening==
*2012: Basch et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion EuroPMC
Category:Guideline pages